Table 2 Characteristics of patients with and without hypocalcemia
Patients without hypocalcemia (n = 337) | Patients with hypocalcemia (n = 187) | P-value | ||
|---|---|---|---|---|
Age (years) | 68.8 ± 11.4 | 68.6 ± 11.0 | 0.542 | |
Sex, male/female (n) | 188/149 | 115/72 | 0.230 | |
Body weight (kg) | 55.5 ± 11.9 (n = 300) | 56.3 ± 11.6 (n = 162) | 0.294 | |
Serum creatinine (mg/dL) | 0.80 ± 0.38 | 0.94 ± 0.66 | 0.009 | |
Creatinine clearance (mL/min) | 67.9 ± 25.2 | 63.7 ± 26.0 | 0.108 | |
Renal function classification | Normal | 104 (31) | 49 (26) | 0.006 |
Mild | 139 (41) | 83 (44) | ||
Moderate | 82 (24) | 35 (19) | ||
Severe | 12 (4) | 20 (11) | ||
Serum calcium level before administration of denosumab (mg/dL) | 9.3 ± 0.9 | 9.0 ± 1.1 | < 0.001 | |
Albumin-adjusted serum calcium level before administration of denosumab (mg/dL) | 9.9 ± 1.0 (n = 328) | 9.6 ± 1.1 (n = 184) | < 0.001 | |
Serum albumin (g/dL) | 3.5 ± 0.7 (n = 328) | 3.5 ± 0.6 (n = 184) | 0.883 | |
Serum phosphorus (mg/dL) | 3.4 ± 0.7 (n = 139) | 3.4 ± 0.7 (n = 105) | 0.611 | |
Cancer type | Lung cancer | 137 (41) | 82 (44) | 0.072 |
Breast cancer | 65 (19) | 27 (14) | ||
Prostate cancer | 48 (14) | 40 (21) | ||
Others | 87 (26) | 38 (20) | ||
Prophylactic administration | Natural vitamin D ± calcium | 281 (82) | 160 (86) | 0.048 |
Active vitamin D ± calcium | 13 (4) | 14 (7) | ||
Calcium only | 1 (1) | 0 (0) | ||
None | 42 (12) | 13 (7) |